For most individuals, the normal range of intraocular pressure is between 10 mmHg and 21 mmHg. Elevated intraocular pressure is an important risk factor for glaucoma. One study found that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Accordingly, most individuals with consistently elevated intraocular pressures of greater than 21mmHg, particularly if they have other risk factors, are treated in an effort to prevent vision loss from glaucoma.
Ocular hypertension is treated with either medications or laser. Medications that lower intraocular pressure work by decreasing aqueous humor production and/or increasing aqueous humor outflow. Laser trabeculoplasty works by increasing outflow. The cannabinoids found in cannabis sativa and indica (marijuana) have been shown to reduce intraocular pressure, by up to 50% for approximately four to five hours. But due to the duration of effect, significant side-effect profile, and lack of research proving efficacy, the American Glaucoma Society issued a position statement in 2009 regarding the use of marijuana as a treatment for glaucoma.
- American Academy of Ophthalmology Archived November 25, 2005, at the Wayback Machine
- American Optometric Association - Ocular Hypertension
- webMD - Tonometry
- "eMedicine - Glaucoma Overview". Archived from the original on 2008-07-04. Retrieved 2005-12-28.
- Kass, M.A. (2002). "The Ocular Hypertension Treatment Study". Arch Ophthalmol. 120 (6): 701–713. doi:10.1001/archopht.120.6.701.
- Salmon, John F., (2020). "Glaucoma". Kanski's clinical ophthalmology : a systematic approach (9th ed.). Edinburgh: Elsevier. ISBN 978-0-7020-7713-5. OCLC 1131846767.CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
- Jampel, H (2010). "American Glaucoma Society Position Statement: Marijuana and the treatment of glaucoma". J Glaucoma. 19 (2): 75–76. doi:10.1097/ijg.0b013e3181d12e39. PMID 20160576.